SK Life Science
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SK Life Science sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
SK Life Science: 25 sponsored US clinical trials, 2 recruiting.
SK Life Science sponsors 25 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 21 completed. 6 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Partial Epilepsy, with 2 trials.
Top-decile sponsor footprint
SK Life Science ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
NCT05572255
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
NCT05388435
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
NCT04903314
Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
NCT04690751
Bioavailability and Food Effect Study of 3 Types of Carisbamate
NCT04520360
Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
NCT04505397
Cenobamate Open-Label Extension Study for YKP3089C025
NCT03961568
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
NCT04062981
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
NCT03731715
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
NCT03678753
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
NCT03509285
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
NCT03234699
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT02535091
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
NCT02205099
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
NCT01989234
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT01866111
A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation
NCT01523184
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy
NCT01521598
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
NCT01397968
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
NCT00616148
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT00109083
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the SK Life Science pipeline
2 recruiting of 25 indexed (8% open); 21 completed (84%).
Phase mix: 6 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Partial Epilepsy (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SK Life Science: open-pipeline peers nationwide
Peers matched on 25 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
SK Life Science sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Medtronic Endovascular · 8% recruiting · 25 trials
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
- Penumbra · 8% recruiting · 25 trials
- Syndax Pharmaceuticals · 8% recruiting · 25 trials
Related
What to do with this SK Life Science page
25 registered trials is a research-attention snapshot, not an endorsement of SK Life Science or any single study.
- 2 of SK Life Science's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Partial Epilepsy is the condition SK Life Science studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Partial Epilepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SK Life Science pipeline card: 25 registered trials from official public datasets.Report a data error.